Burger line Burger line Burger line
Logo Logo Logo
Burger line Burger line Burger line
Sign in
Sign in

Allergan’s trial drug for IBS-D shows positive results in late stage trials


Allergan (NYSE: AGN) on Thursday said The New England Journal of Medicine (NEJM) has published positive results from late stage trials of its Viberzi C IV (eluxadoline) to treat irritable bowel syndrome with diarrhea (IBS-D).

The company said two Phase III trials showed significantly more patients treated with Viberzi experienced improvements in diarrhea and abdominal pain, as compared with placebo. IBS-D is a functional bowel disorder commonly characterized by chronic abdominal pain and frequent diarrhea, which affects approximately 15 million patients in the USA.

David Nicholson, president and executive vice president of global R&D at Allergan, said: "These significant Phase III results highlight the efficacy of Viberzi, demonstrating an exciting new treatment option that provides improvements for two of the most common symptoms of IBS-D, which patients have struggled to address. With so many Americans forced to deal with limited treatment options, Viberzi is an effective first-in-line therapy that is positioned to address a major unmet need."

A total of 1,280 patients in Study 1 and 1,145 patients in Study 2 received treatment with Viberzi 75mg, Viberzi 100mg or placebo twice daily. Overall, the patients were a mean age of 45 years.

Based on efficacy of Viberzi 75mg and 100mg at 12 weeks of treatment, Viberzi was approved by the US Food and Drug Administration as a twice-daily, oral treatment indicated for use in adults suffering from IBS-D. Viberzi has mixed opioid receptor activity – it is a mu receptor agonist, a delta receptor antagonist, and a kappa receptor agonist that acts locally in the gut.



0
Cart Subtotal:
Go to cart
You will be able to Pay Online or Request a Quote

We use "cookies*  to ensure the functionality of our website, recognise your browser or device, learn more about your interests, and provide you with essential features and services and for additional purposes, including:

Recognising you when you sign-in to use our services. This allows us to provide you with product recommendations, display personalised content, and provide other customised features and services.
Keeping track of your specified preferences. You may set your preferences through Your Account..
Keeping track of items stored in your shopping basket and personal cabinet.
Conducting research and diagnostics to improve ChemDiv’s content, products, and services.
Delivering content, including ads, relevant to your interests on ChemDiv’s site
Reporting. This allows us to measure and analyse the performance of our services.

By  cookies you give consent to the processing of your personal data, including transfer to third parties. Further information can be found in our privacy policy.

Accept all cookies